DESCRIPTION (provided by applicant): The Greater Phoenix CCOP is a consortium of five hospitals with 40 investigators, led by principal investigator, David King, MD. Dr. King and many of the investigators have been associated with the CCOP since its inception in 1982. The continuing long-term goals and specific aims of the GPCCOP include: 1) To increase clinical research activities with new and established research bases; 2) To participate in chemoprevention studies supported through other NCI mechanisms, to enhance offerings to GPCCOP's population; 4) To maintain and enhance quality assurance and pharmacy tools to support GPCCOP accrual; 5) To provide for human subject protection and minimal research risk; and 6) To support the disease prevention objectives of "Healthy People 2010" - in particular, to eliminate health disparities among different segments of the population through outreach, affiliations, and recruitment strategies focusing on minorities, women, and the underserved. GPCCOP's organizational structure requires the involvement of the investigators, hospital administrators from each of the participating component organizations and the staff in planning and policy-making decisions. The research activities and resources are split evenly between the treatment segment and the chemoprevention segment of GPCCOP, with each segment achieving accrual and quality goals established by the National Cancer Institute. GPCCOP's outreach is focused on achieving goals of minority and underserved accrual through community affiliations, collaborations, and geographical diversity. By establishing community and tribal partnerships, GPCCOP facilitates an outreach territory encompassing more that 40,000 square miles and 4 counties. GPCCOP's dedication to participant accrual (205 treatment and more than 1000 chemoprevention participants in the past five years), quality assurance, human subject protection, and minority outreach, as well as the devotion of resources from its consortium hospitals, demonstrate its preparedness to continue its active participation in NCI's Community Clinical Oncology Program. COLLABORATING INSTITUTIONS: Good Samaritan Regional Medical Center, Phoenix, AZ John C. Lincoln Health Network, Phoenix, AZ St. Joseph's Hospital and Medical Center, Phoenix, AZ Scottsdale Healthcare, Scottsdale, AZ Thunderbird Samaritan Medical Center, Glendale, AZ
Related Clinical Trials Conducted by the group:
| 1 | Diagnostic Study of EF5 Binding for the Detection of Tumor Hypoxia in Patients With Stage IIB, IIIB, or IVA Cervical Cancer | |
| 2 | Diagnostic Study of Lymphatic Mapping and Sentinel Node Identification in Patients With Stage IB1 Cervical Cancer | |
| 3 | Phase I Pilot Study of Gefitinib in Patients Age 75 and Over or Age 50 and Under With Metastatic or Unresectable Carcinoma of the Head and Neck or Non-Small Cell Lung Cancer | |
| 4 | Phase I Study of Adjuvant Intraperitoneal Carboplatin and Paclitaxel in Patients With Stage III or IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Who Had Initial Debulking Surgery | |
| 5 | Phase I Study of Doxorubicin and Cisplatin Followed By Whole Abdominal Radiotherapy in Patients With Stage III or IV Endometrial Cancer | |
| 6 | Phase I Study of EGFRvIII Peptide Vaccine With Sargramostim (GM-CSF) Versus Keyhole Limpet Hemocyanin as Adjuvant in Patients With EGFRvIII-Expressing Cancer | |
| 7 | Phase I Study of Extended Field Radiotherapy, Cisplatin, and Topotecan in Patients With Locally Advanced Cervical Cancer | |
| 8 | Phase I Study of Intraperitoneal (IP) Carboplatin in Combination With Intravenous (IV) Docetaxel Versus IV Paclitaxel Followed By IP Paclitaxel in Patients With Stage III or IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma | |
| 9 | Phase I Study of Low-Dose Abdominal Radiotherapy and Docetaxel in Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer | |
| 10 | Phase I Study of Paclitaxel and Cisplatin With Radiotherapy in Patients With Stage III or IV Endometrial Cancer | |
| 11 | Phase I Study of Polyglutamate Paclitaxel and Carboplatin in Patients With Chemotherapy-Na??A?ve Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Carcinoma | |
| 12 | Phase I Study of Whole Pelvic Radiotherapy and Concurrent Cisplatin and Gemcitabine in Patients With Cervical Carcinoma Limited to the Pelvis | |
| 13 | Phase I/II Study of Extended Field Radiotherapy With Concurrent Paclitaxel and Cisplatin Chemotherapy in Patients With Previously Untreated Carcinoma of the Cervix Metastatic to the Para-aortic Lymph Nodes | |
| 14 | Phase I/II Study of Radiotherapy Combined With Paclitaxel and Cisplatin in Patients With Stage IB2, IIA, IIB, IIIB, or IVA Invasive Carcinoma of the Cervix | |
| 15 | Phase II Pilot Study of Docetaxel, Cisplatin, and Fluorouracil Followed By Accelerated Fractionation/Concomitant Boost Radiotherapy and Concurrent Cisplatin in Patients With Stage III or IV Squamous Cell Carcinoma of the Head and Neck | |
| 16 | Phase II Pilot Study of Medroxyprogesterone in Patients With Endometrioid Adenocarcinoma of the Uterine Corpus | |
| 17 | Phase II Pilot Study of Rituximab and Alternating Chemotherapy Regimens in Patients With Previously Untreated Mantle Cell Lymphoma | |
| 18 | Phase II Pilot Study of Trastuzumab (Herceptin), Docetaxel, and Vinorelbine With Filgrastim (G-CSF) Support in Women With HER2-Positive Stage IV Breast Cancer | |
| 19 | Phase II Randomized Study of Celecoxib in Patients With Cervical Intraepithelial Neoplasia 3 | |
| 20 | Phase II Randomized Study of Celecoxib in Premenopausal Women at High Risk for Developing Breast Cancer | |
| 21 | Phase II Randomized Study of Concurrent Versus Sequential Paclitaxel, Carboplatin, and Cetuximab in Patients With Selected Stage IIIB or Stage IV Non-Small Cell Lung Cancer | |
| 22 | Phase II Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab With or Without Epratuzumab in Patients Age 60 and Over With Previously Untreated Stage III or IV or Bulky Stage II Diffuse Large B-Cell Non-Hodgkin's Lymphoma | |
| 23 | Phase II Randomized Study of Imatinib Mesylate at Standard Versus Increased Dose Alone Versus Imatinib Mesylate and Cytarabine Versus Imatinib Mesylate and PEG-Interferon alfa-2a in Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia | |
| 24 | Phase II Randomized Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma | |
| 25 | Phase II Randomized Study of SGN-00101 in Patients With Grade III Cervical Intraepithelial Neoplasia | |
| 26 | Phase II Study of 3-AP and Cisplatin in Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | |
| 27 | Phase II Study of Adjuvant Chemoradiotherapy Comprising Cisplatin and Docetaxel After Complete Resection in Patients With Stage III or IV Squamous Cell Carcinoma of the Head and Neck | |
| 28 | Phase II Study of Allogeneic Peripheral Blood Stem Cell Transplantation With Pre-Conditioning Low-Dose Total Body Irradiation and Fludarabine Followed By Mycophenolate Mofetil and Cyclosporine in Elderly Patients With Acute Myeloid Leukemia in First Complete Remission | |
| 29 | Phase II Study of Arsenic Trioxide in Men With Refractory Testicular or Extragonadal Germ Cell Malignancies | |
| 30 | Phase II Study of Bevacizumab in Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | |
| 31 | Phase II Study of Bevacizumab in Patients With Persistent or Recurrent Squamous Cell Carcinoma of the Cervix | |
| 32 | Phase II Study of Bevacizumab in Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma | |
| 33 | Phase II Study of Bortezomib in Patients With Persistent or Recurrent Platinum-Sensitive Ovarian Epithelial or Primary Peritoneal Carcinoma | |
| 34 | Phase II Study of Bortezomib in Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Therapy | |
| 35 | Phase II Study of Capecitabine in Elderly Patients With Unresectable Metastatic or Recurrent Colorectal Cancer | |
| 36 | Phase II Study of Capecitabine in Patients With Persistent or Recurrent Non-Squamous Cell Carcinoma of the Cervix | |
| 37 | Phase II Study of Cetuximab and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Epithelial or Primary Peritoneal Cancer | |
| 38 | Phase II Study of Complete Surgical Resection in Patients With Stage IV Melanoma | |
| 39 | Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone and Radiotherapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Aggressive Stage I or IE or Non-Bulky Stage II or IIE CD20-Positive Non-Hodgkin's Lymphoma | |
| 40 | Phase II Study of Docetaxel in Elderly Women With Metastatic Breast Cancer | |
| 41 | Phase II Study of Docetaxel in Patients With Locally Advanced or Metastatic Epidermoid Carcinoma of the Penis | |
| 42 | Phase II Study of Docetaxel in Patients With Persistent or Recurrent Squamous Cell Carcinoma of the Cervix | |
| 43 | Phase II Study of Docetaxel in Patients With Recurrent or Persistent Endometrial Carcinoma | |
| 44 | Phase II Study of Early Estramustine, Etoposide, and Paclitaxel With Combined Androgen Blockade Therapy in Patients With High-Risk Metastatic Adenocarcinoma of the Prostate | |
| 45 | Phase II Study of Erlotinib in Patients With Advanced Primary Non-Small Cell Lung Cancer and a Zubrod Performance Status of 2 | |
| 46 | Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer | |
| 47 | Phase II Study of Erlotinib in Patients With Persistent or Recurrent Squamous Cell Carcinoma of the Cervix | |
| 48 | Phase II Study of Erlotinib in Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor | |
| 49 | Phase II Study of FR901228 in Patients With Advanced Transitional Cell Carcinoma of the Urothelium That Has Progressed After Prior Chemotherapy | |
| 50 | Phase II Study of FR901228 in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer | |
| 51 | Phase II Study of GVAX Lung Cancer Vaccine in Patients With Selected Stage IIIB or Stage IV Bronchoalveolar Carcinoma | |
| 52 | Phase II Study of Gemcitabine and Capecitabine in Patients With Advanced Renal Cell Cancer | |
| 53 | Phase II Study of Gemcitabine and Paclitaxel in Patients With Advanced or Recurrent Urothelial Cancer | |
| 54 | Phase II Study of Gemcitabine, Carboplatin, and Bortezomib in Patients With Chemotherapy-Na??A?ve Advanced or Recurrent Non-Small Cell Lung Cancer | |
| 55 | Phase II Study of Gemtuzumab Ozogamicin and Cytarabine in Patients With Relapsed Acute Myeloid Leukemia | |
| 56 | Phase II Study of High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in Patients With High-Risk Multiple Myeloma or Primary Systemic Amyloidosis | |
| 57 | Phase II Study of Hydroxyurea in Patients With Unresectable Benign Meningioma | |
| 58 | Phase II Study of ICI 182780 in Patients With Recurrent or Metastatic Endometrial Cancer | |
| 59 | Phase II Study of Imatinib Mesylate and Capecitabine in Women With Progressive Stage IV Adenocarcinoma of the Breast | |
| 60 | Phase II Study of Imatinib Mesylate in Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans (DFSP) or Transformed Fibrosarcomatous DFSP | |
| 61 | Phase II Study of Imatinib Mesylate in Patients With Metastatic or Unresectable Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma) | |
| 62 | Phase II Study of Imatinib Mesylate in Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Carcinoma | |
| 63 | Phase II Study of Imatinib Mesylate in Patients With Platinum- and Taxane-Refractory Stage III or IV Ovarian Epithelial or Primary Peritoneal Cancer | |
| 64 | Phase II Study of Imatinib Mesylate in Patients With Recurrent or Persistent Uterine Carcinosarcoma | |
| 65 | Phase II Study of Induction Tirapazamine, Cisplatin, and Etoposide With Concurrent Thoracic Radiotherapy Followed By Consolidation Cisplatin and Etoposide in Patients With Limited Stage Small Cell Lung Cancer | |
| 66 | Phase II Study of Irinotecan in Patients With Recurrent or Refractory Advanced Transitional Cell Carcinoma of the Urothelium Previously Treated With Platinum-Based Chemotherapy | |
| 67 | Phase II Study of Irofulven in Patients With Recurrent or Persistent Platinum-Sensitive Ovarian Epithelial or Primary Peritoneal Cancer | |
| 68 | Phase II Study of Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed By Concurrent Cisplatin and Radiotherapy in Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium | |
| 69 | Phase II Study of Neoadjuvant Gemcitabine, Paclitaxel, and Carboplatin Followed By Observation or Immediate Cystectomy in Patients With Stage II or III Transitional Cell Cancer of the Urothelium | |
| 70 | Phase II Study of Neoadjuvant Oxaliplatin, Fluorouracil, and Radiotherapy Followed By Definitive Surgical Resection in Patients With Stage II or III Squamous Cell Carcinoma or Adenocarcinoma of the Esophagus or Gastroesophageal Junction | |
| 71 | Phase II Study of Neoadjuvant Paclitaxel and Carboplatin Followed By Surgery and Adjuvant Paclitaxel and Carboplatin in Patients With Stage III or IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | |
| 72 | Phase II Study of Nitrocamptothecin in Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer | |
| 73 | Phase II Study of Paclitaxel and Celecoxib in Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | |
| 74 | Phase II Study of Paclitaxel in Patients With Ovarian Stromal Cancer | |
| 75 | Phase II Study of Paclitaxel, Cisplatin, and Doxorubicin HCl Liposome in Patients With Optimally Debulked Stage III Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | |
| 76 | Phase II Study of Pemetrexed Disodium in Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | |
| 77 | Phase II Study of Pemetrexed Disodium in Patients With Recurrent Carcinoma of the Cervix | |
| 78 | Phase II Study of Pemetrexed Disodium in Patients With Persistent or Recurrent Endometrial Adenocarcinoma | |
| 79 | Phase II Study of Radiotherapy and Cisplatin Followed By Resection of Residual Disease in Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva That is Not Amenable to Standard Radical Vulvectomy | |
| 80 | Phase II Study of Surgery and Ad5CMV-p53 Gene Followed By Cisplatin and Radiotherapy in Patients With Newly Diagnosed Resectable Stage III or IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx | |
| 81 | Phase II Study of Targeted Induction Chemotherapy Followed By Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Rectum | |
| 82 | Phase II Study of Thalidomide and Dexamethasone Induction Followed By Tandem Melphalan and Peripheral Blood Stem Cell Transplantation Followed By Prednisone and Thalidomide Maintenance in Patients With Multiple Myeloma | |
| 83 | Phase II Study of Topotecan in Patients With Persistent or Recurrent Carcinoma of the Cervix | |
| 84 | Phase II Study of Trastuzumab (Herceptin??A?) in Patients With Advanced, Recurrent, or Persistent Endometrial Adenocarcinoma | |
| 85 | Phase II/III Randomized Study of Ginger for Chemotherapy-Related Nausea in Patients With Cancer | |
| 86 | Phase III Randomized Adjuvant Study of Tumor Volume-Directed Pelvic Radiotherapy With or Without Paraaortic Radiotherapy Followed By Cisplatin and Doxorubicin With or Without Paclitaxel in Patients With Stage III Endometrial Carcinoma | |
| 87 | Phase III Randomized Chemoprevention Study of Celecoxib in Patients With Resected Stage I Adenocarcinoma of the Colon | |
| 88 | Phase III Randomized Study of Adjuvant Androgen Deprivation Therapy With or Without Mitoxantrone and Prednisone After Radical Prostatectomy in Patients With High-Risk Adenocarcinoma of the Prostate | |
| 89 | Phase III Randomized Study of Adjuvant Fluorouracil, Epirubicin, and Cyclophosphamide With or Without Celecoxib Versus Doxorubicin and Cyclophosphamide With or Without Celecoxib in Women With Node-Negative Breast Cancer | |
| 90 | Phase III Randomized Study of Amifostine Versus No Treatment For Platinum-Induced Peripheral Neuropathy in Patients With Gynecologic Malignancies | |
| 91 | Phase III Randomized Study of Anastrozole Versus Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ of the Breast Undergoing Lumpectomy and Radiotherapy | |
| 92 | Phase III Randomized Study of Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer | |
| 93 | Phase III Randomized Study of Carboplatin With or Without Pegylated Doxorubicin HCl Liposome in Patients With Platinum-Sensitive Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | |
| 94 | Phase III Randomized Study of Carboplatin and Paclitaxel With or Without Low-Dose Paclitaxel in Patients With Early Stage Ovarian Carcinoma | |
| 95 | Phase III Randomized Study of Cisplatin Only Versus Cisplatin Plus Topotecan Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix | |
| 96 | Phase III Randomized Study of Cisplatin and Irinotecan Versus Cisplatin and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer | |
| 97 | Phase III Randomized Study of Cisplatin, Etoposide, Radiotherapy, and Docetaxel With or Without Gefitinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | |
| 98 | Phase III Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) With Either Rituximab or Iodine I 131 Tositumomab (Monoclonal Antibody Anti-B1) in Patients With Newly Diagnosed Follicular Non-Hodgkin's Lymphoma | |
| 99 | Phase III Randomized Study of Dexamethasone With or Without CC-5013 in Patients With Newly Diagnosed Multiple Myeloma | |
| 100 | Phase III Randomized Study of Doxorubicin and Cyclophosphamide Followed By Paclitaxel With or Without Trastuzumab (Herceptin) in Women With Node-Positive Breast Cancer That Overexpresses HER2 | |
| 101 | Phase III Randomized Study of Doxorubicin, Cisplatin, Paclitaxel, and Filgrastim (G-CSF) Versus Carboplatin and Paclitaxel in Patients With Stage III or IV or Recurrent Endometrial Cancer | |
| 102 | Phase III Randomized Study of Fibrin Sealant to Reduce Lymphedema Incidence After Lymph Node Dissection in Patients With Vulvar Malignancies | |
| 103 | Phase III Randomized Study of Fluorouracil, Leucovorin Calcium, and Oxaliplatin Versus Capecitabine and Oxaliplatin With or Without Bevacizumab in Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer | |
| 104 | Phase III Randomized Study of Four Schedules of Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Patients With Node-Positive or High-Risk Node-Negative Breast Cancer | |
| 105 | Phase III Randomized Study of Gemcitabine With Versus Without Cetuximab as First-Line Therapy in Patients With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas | |
| 106 | Phase III Randomized Study of Gemcitabine With or Without Dalteparin in Patients With Unresectable or Metastatic Pancreatic Cancer | |
| 107 | Phase III Randomized Study of Goserelin for the Reduction of Premature Ovarian Failure in Women With Stage I-IIIA Hormone Receptor-Negative Breast Cancer Undergoing Adjuvant Chemotherapy | |
| 108 | Phase III Randomized Study of Induction Therapy Comprising Cytarabine and Daunorubicin With Versus Without Gemtuzumab Ozogamicin Followed By Consolidation Therapy Comprising High-Dose Cytarabine and Post-Consolidation Therapy Comprising Gemtuzumab Ozogamicin Versus No Additional Therapy in Patients With Previously Untreated De Novo Acute Myeloid Leukemia | |
| 109 | Phase III Randomized Study of Interferon alfa Versus Cisplatin, Vinblastine, and Dacarbazine Plus Interferon alfa and Interleukin-2 in Patients With High-Risk Melanoma | |
| 110 | Phase III Randomized Study of Interleukin-2 Versus Observation Only After Total Body Irradiation, High-Dose Etoposide, Cyclophosphamide, and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Adult Non-Hodgkin's Lymphoma | |
| 111 | Phase III Randomized Study of Intermittent Versus Continuous Combined Androgen-Deprivation Therapy Comprising Bicalutamide and Goserelin in Patients With Metastatic Stage IV Prostate Cancer Responsive to Such Therapy | |
| 112 | Phase III Randomized Study of L-Glutamine For Radiotherapy-Induced Oral Mucositis in Patients With Newly Diagnosed, Previously Untreated Squamous Cell Cancer of the Oral Cavity or Oropharynx Receiving High-Dose Radiotherapy | |
| 113 | Phase III Randomized Study of Medroxyprogesterone Acetate Versus Observation for Prevention of Endometrial Pathology in Postmenopausal Women With Breast Cancer Treated With Adjuvant Tamoxifen | |
| 114 | Phase III Randomized Study of Methotrexate Versus Dactinomycin in Patients With Low-Risk Gestational Trophoblastic Neoplasia | |
| 115 | Phase III Randomized Study of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Versus Observation Alone Based on p53 Gene Status in Patients With Organ Confined Transitional Cell Carcinoma of the Bladder Who Have Undergone Radical Cystectomy and Bilateral Pelvic Lymphadenectomy | |
| 116 | Phase III Randomized Study of Modafinil for Fatigue in Cancer Patients Receiving Chemotherapy | |
| 117 | Phase III Randomized Study of Octreotide Versus Standard Care for Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer | |
| 118 | Phase III Randomized Study of Paclitaxel and Carboplatin With or Without Gemcitabine, Doxorubicin HCl Liposome, or Topotecan in Patients With Stage III or IV Ovarian Epithelial or Serous Primary Peritoneal Carcinoma | |
| 119 | Phase III Randomized Study of Paclitaxel and Cisplatin Versus Vinorelbine and Cisplatin Versus Gemcitabine and Cisplatin Versus Topotecan and Cisplatin in Patients With Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix | |
| 120 | Phase III Randomized Study of Preoperative Capecitabine and Radiotherapy Versus Fluorouracil and Radiotherapy in Patients With Resectable Rectal Cancer | |
| 121 | Phase III Randomized Study of Radical Hysterectomy and Tailored Chemoradiotherapy Versus Primary Chemoradiotherapy in Patients With Stage IB2 Carcinoma of the Cervix | |
| 122 | Phase III Randomized Study of Radiotherapy and Carmustine With or Without O6-Benzylguanine in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | |
| 123 | Phase III Randomized Study of Selenium as Chemoprevention of Prostate Cancer in Patients With High-Grade Prostatic Intraepithelial Neoplasia | |
| 124 | Phase III Randomized Study of Standard Neoadjuvant Doxorubicin and Cyclophosphamide Followed By Weekly Paclitaxel Versus Weekly Doxorubicin and Daily Oral Cyclophosphamide With Filgrastim (G-CSF) Followed By Weekly Paclitaxel in Women With Inflammatory or Locally Advanced Breast Cancer | |
| 125 | Phase III Randomized Study of Surgery With or Without Preoperative Paclitaxel and Carboplatin in Patients With Stage IB, II, or Selected IIIA Non-Small Cell Lung Cancer | |
| 126 | Phase III Randomized Study of Tamoxifen Versus Thalidomide in Patients With Only a Biochemical Recurrence of Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer After First-Line Chemotherapy | |
| 127 | Phase III Randomized Study of Vaginal Hysterectomy and Bilateral Salpingo-Oophorectomy (BSO) Via Laparoscopy Versus Total Abdominal Hysterectomy and BSO Via Conventional Laparotomy Plus Pelvic and Para-Aortic Lymph Node Sampling in Patients With Stage I or IIA, Grade I-III Endometrial Cancer or Uterine Cancer | |
| 128 | Phase III Randomized Study of Whole Abdominal Radiotherapy Versus Ifosfamide and Cisplatin in Patients With Optimally Debulked Stage I-IV Carcinosarcoma of the Uterus | |
| 129 | Phase III Study of Early High-Dose Chemoradiotherapy and Autologous Peripheral Blood Stem Cell Transplantation Versus Conventional Dose Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Intermediate- or High-Grade Non-Hodgkin's Lymphoma | |
| 130 | Phase III Study of Intraoperative Lymphatic Mapping in Patients With Invasive Squamous Cell Carcinoma of the Vulva | |
| 131 | Phase IIb Randomized Study of Celecoxib in Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix | |
| 132 | Pilot Study to Correlate DNA Sequence Copy Number Abnormalities With Outcome in Patients With Advanced Epithelial Ovarian Cancer | |
| 133 | Prospective Screening Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA 125 Screening in Participants at Increased Genetic Risk of Ovarian Cancer | |
| 134 | Randomized Study of Co-Trimoxazole Versus Ciprofloxacin or Ofloxacin Versus No Prophylaxis for the Prevention of Early Infection in Patients With Multiple Myeloma | |
| 135 | Randomized Study of Fenretinide as Chemoprevention in Patients at Increased Risk for Ovarian Cancer | |
| 136 | Study of MN Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Neoplasia in Patients With Atypical Glandular Cells of Undetermined Significance | |
| 137 | Study of Multicolor Fluorescence Immunocytochemistry and Bright Field Immunocytochemistry for the Detection of Tumor Cells in Bone Marrow of Women With Stage I, II, or IIIA Breast Cancer Undergoing Surgery | |
| 138 | Study of Vaginal Length, Elasticity, Lubrication, and Sexual Function in Patients With Stage IB2 Cervical Cancer | |
| 139 | Supportive-Expressive Group Therapy for Men with Stage I/II Prostate Cancer | |
This project is coded as follows:
Type of Cancer Research Codes:
- Education and Communication
- Resources and Infrastructure Related to Cancer Control, Survivorship, and Outcomes Research
Type of Cancer Codes:
- Bladder Cancer
- Blood Cancer
- Bone Marrow Transplantation
- Brain Tumor
- Breast Cancer
- Cervical Cancer
- Colon and Rectal Cancer
- Esophageal Cancer
- Gastrointestinal Tract
- Genital System, Female
- Genital System, Male
- Head and Neck Cancer
- Leukemia
- Lung Cancer
- Melanoma
- Myeloma
- Nervous System
- Non-Hodgkin's Lymphoma
- Not Site-Specific Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Respiratory System
- Skin Cancer
- Stomach Cancer
- Testicular Cancer
- Urinary System
E-Mail this page
Define terms on this page
View related clinical trials conducted by this group